Patrick Westmoreland
About Patrick Westmoreland
Patrick Westmoreland is a Principal Scientist at Bristol Myers Squibb, specializing in Viral Vector and Gene Editing Process Development.
Current Position at Bristol Myers Squibb
Patrick Westmoreland currently holds the position of Principal Scientist, Viral Vector and Gene Editing Process Development at Bristol Myers Squibb. In this role, he manages a diverse team of scientists and engineers to develop upstream and downstream processes for AAV (adeno-associated virus) production. His responsibilities include strategic planning for the development of an internal AAV platform process and assessing novel technologies to improve product quality and total titer output to increase the commercial feasibility of rAAV vectors.
Previous Roles at Bristol Myers Squibb
Before his current role, Patrick Westmoreland served as Senior Scientist, Viral Vector Process Development at Bristol Myers Squibb from 2019 to 2021 in Seattle, Washington. During this period, he gained valuable experience in process development for manufacturing rAAV vectors including CDMO (Contract Development and Manufacturing Organization) management. His work contributed to advancing the company's viral vector and gene editing initiatives.
Experience at Abeona Therapeutics
Prior to joining Bristol Myers Squibb, Patrick Westmoreland worked at Abeona Therapeutics. He served as Senior Scientist, Process Development in 2019 for five months and as Scientist, Process Development from 2018 to 2019 for one year, both in Cleveland, Ohio. In these roles, he focused on process development tasks essential for the company's biopharmaceutical production, honing his expertise in the field.
Academic Background and Early Career
Patrick Westmoreland has a strong academic foundation in biochemistry and molecular biology. He earned his Bachelor of Science from Wittenberg University, where he was a lab assistant in both chemistry and cellular and molecular biology, and a math workshop tutor. Additionally, he completed undergraduate research in 2010. Patrick later pursued advanced studies at The Ohio State University, obtaining a Ph.D. in Molecular, Cellular, and Developmental Biology (MCDB). He also served as a Graduate Research Assistant and held various roles, including Recruitment Chair for the OSU MCDB Executive Board.
Commitment to Rare Disease Treatments
Patrick Westmoreland is motivated to develop treatments for patients and families affected by rare diseases. This personal drive stems from having a family member affected by a rare disease. His professional endeavors are aligned with this mission, leveraging his extensive experience in rAAV vector process development to bring potential therapies closer to those in need.